BIX0 Stock Overview
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIX0 from our risk checks.
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.08 |
| 52 Week High | kr2.55 |
| 52 Week Low | kr1.17 |
| Beta | 0.33 |
| 1 Month Change | 43.90% |
| 3 Month Change | 43.10% |
| 1 Year Change | -18.47% |
| 3 Year Change | -53.68% |
| 5 Year Change | -1.19% |
| Change since IPO | -87.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIX0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.5% | 0.7% | 2.0% |
| 1Y | -18.5% | -24.4% | 2.0% |
Return vs Industry: BIX0 exceeded the German Biotechs industry which returned -22.8% over the past year.
Return vs Market: BIX0 underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| BIX0 volatility | |
|---|---|
| BIX0 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BIX0's share price has been volatile over the past 3 months.
Volatility Over Time: BIX0's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 109 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
BioInvent International AB (publ) Fundamentals Summary
| BIX0 fundamental statistics | |
|---|---|
| Market cap | €141.46m |
| Earnings (TTM) | -€28.59m |
| Revenue (TTM) | €5.23m |
27.1x
P/S Ratio-4.9x
P/E RatioIs BIX0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIX0 income statement (TTM) | |
|---|---|
| Revenue | kr61.15m |
| Cost of Revenue | kr0 |
| Gross Profit | kr61.15m |
| Other Expenses | kr395.67m |
| Earnings | -kr334.52m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -5.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | -547.02% |
| Debt/Equity Ratio | 0% |
How did BIX0 perform over the long term?
See historical performance and comparison